In this respect, an agent that could simultaneously suppress vascular endothelial growth factor (VEGF) and other pathways involved in metastasis and multidrug resistance is an appropriate therapy for CRC patients with osteosarcoma. Here, VEGFA is linked to colorectal carcinoma.